NASDAQ:MDRX Veradigm (MDRX) Stock Forecast, Price & News $11.76 -0.02 (-0.17%) (As of 10:28 AM ET) Add Compare Share Share Today's Range$11.69▼$11.8550-Day Range$11.77▼$13.1552-Week Range$11.57▼$19.77Volume96,638 shsAverage Volume1.11 million shsMarket Capitalization$1.28 billionP/E Ratio27.35Dividend YieldN/APrice Target$19.58 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Veradigm MarketRank™ ForecastAnalyst RatingHold2.17 Rating ScoreUpside/Downside66.2% Upside$19.58 Price TargetShort InterestHealthy8.48% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment1.36Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth13.64%From $0.66 to $0.75 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.55 out of 5 starsBusiness Services Sector68th out of 347 stocksComputer Integrated Systems Design Industry6th out of 40 stocks 3.1 Analyst's Opinion Consensus RatingVeradigm has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.58, Veradigm has a forecasted upside of 66.2% from its current price of $11.78.Amount of Analyst CoverageVeradigm has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.48% of the float of Veradigm has been sold short.Short Interest Ratio / Days to CoverVeradigm has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Veradigm has recently decreased by 6.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeradigm does not currently pay a dividend.Dividend GrowthVeradigm does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeradigm has received a 59.51% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Computerized clinical decision support software", "Personal health record software", and "Documentation software for clinicians" products. See details.Environmental SustainabilityThe Environmental Impact score for Veradigm is -0.62. Previous Next 2.4 News and Social Media Coverage News SentimentVeradigm has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Veradigm this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for MDRX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Veradigm to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veradigm insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.29% of the stock of Veradigm is held by insiders.Percentage Held by Institutions99.76% of the stock of Veradigm is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Veradigm are expected to grow by 13.64% in the coming year, from $0.66 to $0.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veradigm is 27.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.76.Price to Earnings Ratio vs. SectorThe P/E ratio of Veradigm is 27.40, which means that it is trading at a less expensive P/E ratio than the Business Services sector average P/E ratio of about 269.21.Price to Earnings Growth RatioVeradigm has a PEG Ratio of 1.13. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVeradigm has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Veradigm (NASDAQ:MDRX) StockVeradigm, Inc. engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segments. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units. The firm solutions include All EMRs, All Population Health Management, Patient Engagement, and Precision Medicine. The company was founded in 1986 and is headquartered in Chicago, IL.Read More Receive MDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter. Email Address MDRX Stock News HeadlinesMay 19, 2023 | benzinga.comDo Options Traders Know Something About Veradigm Stock We Don't?May 19, 2023 | msn.comDo Options Traders Know Something About Veradigm (MDRX) Stock We Don't?June 1, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.May 18, 2023 | americanbankingnews.comVeradigm (NASDAQ:MDRX) Now Covered by Analysts at StockNews.comMay 13, 2023 | wsj.comVeradigm Inc.May 9, 2023 | americanbankingnews.comBrokerages Set Veradigm Inc. (NASDAQ:MDRX) PT at $19.58May 6, 2023 | finance.yahoo.comInvestors Will Want Veradigm's (NASDAQ:MDRX) Growth In ROCE To PersistApril 24, 2023 | ca.finance.yahoo.comVeradigm Inc. (MDRX)June 1, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.April 14, 2023 | americanbankingnews.comStephens Begins Coverage on Veradigm (NASDAQ:MDRX)April 14, 2023 | americanbankingnews.comBrokerages Set Veradigm Inc. (NASDAQ:MDRX) PT at $20.90April 13, 2023 | americanbankingnews.comHead-To-Head Analysis: Veradigm (NASDAQ:MDRX) and Aurora Innovation (NASDAQ:AUR)April 12, 2023 | finance.yahoo.comVeradigm Inc. (NASDAQ:MDRX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?March 25, 2023 | americanbankingnews.comVeradigm (NASDAQ:MDRX) Issues FY23 Earnings GuidanceMarch 24, 2023 | americanbankingnews.comVeradigm (NASDAQ:MDRX) Releases FY 2023 Earnings GuidanceMarch 23, 2023 | finance.yahoo.comVeradigm Network Solution Practice Fusion EHR Receives Top RankingMarch 22, 2023 | finance.yahoo.comVeradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing, Provides Update on 4th Quarter and Full Fiscal Year 2022 Reporting of ResultsMarch 22, 2023 | americanbankingnews.comVeradigm Inc. (NASDAQ:MDRX) Receives $20.90 Consensus Target Price from BrokeragesMarch 20, 2023 | finance.yahoo.comDespite shrinking by US$50m in the past week, Veradigm (NASDAQ:MDRX) shareholders are still up 139% over 3 yearsMarch 14, 2023 | finance.yahoo.comVeradigm Practice Management Ranks First in Practice Management Solutions from Black Book™ ResearchMarch 11, 2023 | prnewswire.comROSEN, A RANKED AND LEADING FIRM, Encourages Veradigm Inc. Investors to Inquire About Class Action Investigation - MDRXMarch 1, 2023 | businesswire.comThe Law Offices of Frank R. Cruz Continues Investigation of Veradigm Inc. (MDRX) on Behalf of InvestorsMarch 1, 2023 | finance.yahoo.comVeradigm Inc. Update on 4th Quarter and Full Fiscal Year 2022 Reporting of ResultsFebruary 28, 2023 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Veradigm Inc. (MDRX) on Behalf of InvestorsFebruary 22, 2023 | finance.yahoo.comVeradigm Announces Two New Appointments to Its BoardFebruary 21, 2023 | finance.yahoo.comVeradigm to Release Fourth Quarter and Fiscal Year 2022 Financial Results March 1February 13, 2023 | finance.yahoo.comVeradigm and HealthVerity Collaborate to Advance Real-World Evidence and Care for Patients with Cardiovascular Disease and DiabetesSee More Headlines MDRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDRX Company Calendar Last Earnings11/04/2021Today6/01/2023Next Earnings (Estimated)6/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Computer integrated systems design Sub-IndustryHealth Care Technology SectorBusiness Services Current SymbolNASDAQ:MDRX CUSIP01988P10 CIK1124804 Webwww.allscripts.com Phone(800) 334-8534Fax313-322-9600Employees8,000Year Founded1986Price Target and Rating Average Stock Price Forecast$19.58 High Stock Price Forecast$26.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+66.2%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.43 Trailing P/E Ratio27.40 Forward P/E Ratio17.85 P/E Growth1.12Net Income$134.44 million Net Margins7.25% Pretax Margin14.59% Return on Equity10.74% Return on Assets6.68% Debt Debt-to-Equity Ratio0.17 Current Ratio3.20 Quick Ratio3.20 Sales & Book Value Annual Sales$1.50 billion Price / Sales0.86 Cash Flow$2.73 per share Price / Cash Flow4.32 Book Value$11.49 per share Price / Book1.03Miscellaneous Outstanding Shares109,260,000Free Float106,758,000Market Cap$1.29 billion OptionableOptionable Beta0.94 Social Links Key ExecutivesRichard J. PoultonChief Executive Officer & DirectorThomas LanganPresidentRick DipperChief of Staff & Head-Business OperationsLeah JonesChief Financial & Accounting OfficerJoseph R. RostockChief Technology Officer & SVP-Product EngineeringKey CompetitorsTDCXNYSE:TDCXAurora InnovationNASDAQ:AURSmartRentNYSE:SMRTTuSimpleNASDAQ:TSPKyndrylNYSE:KDView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,388 shares on 5/26/2023Ownership: 0.014%Royce & Associates LPBought 53,491 shares on 5/23/2023Ownership: 0.083%Putnam Investments LLCBought 551,077 shares on 5/22/2023Ownership: 0.615%Ameriprise Financial Inc.Bought 85,521 shares on 5/22/2023Ownership: 0.594%New York State Common Retirement FundSold 35,893 shares on 5/18/2023Ownership: 0.068%View All Insider TransactionsView All Institutional Transactions MDRX Stock - Frequently Asked Questions Should I buy or sell Veradigm stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares. View MDRX analyst ratings or view top-rated stocks. What is Veradigm's stock price forecast for 2023? 6 Wall Street analysts have issued 12 month price objectives for Veradigm's stock. Their MDRX share price forecasts range from $13.00 to $26.00. On average, they expect the company's stock price to reach $19.58 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price. View analysts price targets for MDRX or view top-rated stocks among Wall Street analysts. How have MDRX shares performed in 2023? Veradigm's stock was trading at $17.64 at the beginning of 2023. Since then, MDRX stock has decreased by 33.2% and is now trading at $11.78. View the best growth stocks for 2023 here. When is Veradigm's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 1st 2023. View our MDRX earnings forecast. How were Veradigm's earnings last quarter? Veradigm Inc. (NASDAQ:MDRX) announced its quarterly earnings data on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. The software maker had revenue of $369 million for the quarter, compared to analyst estimates of $376.09 million. Veradigm had a trailing twelve-month return on equity of 10.74% and a net margin of 7.25%. Veradigm's revenue was down 8.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 earnings per share. What ETFs hold Veradigm's stock? ETFs with the largest weight of Veradigm (NASDAQ:MDRX) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Invesco Dynamic Software ETF (PSJ), Fidelity Digital Health ETF (FDHT), Harbor Health Care ETF (MEDI), Invesco S&P SmallCap Health Care ETF (PSCH), Cambria Shareholder Yield ETF (SYLD), Pacer US Small Cap Cash Cows 100 ETF (CALF) and First Trust Active Factor Small Cap ETF (AFSM). What guidance has Veradigm issued on next quarter's earnings? Veradigm issued an update on its FY 2023 earnings guidance on Wednesday, March, 22nd. The company provided earnings per share (EPS) guidance of $0.80-$0.90 for the period, compared to the consensus estimate of $0.90. The company issued revenue guidance of $615.00 million-$635.00 million, compared to the consensus revenue estimate of $649.05 million. What is Paul Black's approval rating as Veradigm's CEO? 796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees. What other stocks do shareholders of Veradigm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI). What is Veradigm's stock symbol? Veradigm trades on the NASDAQ under the ticker symbol "MDRX." Who are Veradigm's major shareholders? Veradigm's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (18.73%), Dimensional Fund Advisors LP (8.34%), State Street Corp (3.63%), William Blair Investment Management LLC (3.13%), Fisher Asset Management LLC (2.68%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include David B Stevens, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Leah Jones, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton, Tejal Vakharia and Thomas Langan. View institutional ownership trends. How do I buy shares of Veradigm? Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Veradigm's stock price today? One share of MDRX stock can currently be purchased for approximately $11.78. How much money does Veradigm make? Veradigm (NASDAQ:MDRX) has a market capitalization of $1.29 billion and generates $1.50 billion in revenue each year. The software maker earns $134.44 million in net income (profit) each year or $0.43 on an earnings per share basis. How many employees does Veradigm have? The company employs 8,000 workers across the globe. Does Veradigm have any subsidiaries? The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.Read More How can I contact Veradigm? Veradigm's mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The official website for the company is www.allscripts.com. The software maker can be reached via phone at (800) 334-8534, via email at stephen.shulstein@allscripts.com, or via fax at 313-322-9600. This page (NASDAQ:MDRX) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veradigm Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.